Pharmacokinetic study of the oral fluorouracil antitumor agent S‐1 in patients with impaired renal function

Although dose reduction of S‐1 is recommended for patients with impaired renal function, dose modification for such patients has not been prospectively evaluated. The aim of the present study was to investigate the pharmacokinetic parameters of 5‐fluorouracil, 5‐chloro‐2,4 dihydroxypyridine and oter...

Descripción completa

Detalles Bibliográficos
Autores principales: Goto, Keiko, Fujiwara, Yutaka, Isobe, Takeshi, Chayahara, Naoko, Kiyota, Naomi, Mukohara, Toru, Tsubata, Yukari, Hotta, Takamasa, Tamura, Kenji, Yamamoto, Noboru, Minami, Hironobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550132/
https://www.ncbi.nlm.nih.gov/pubmed/30989775
http://dx.doi.org/10.1111/cas.14025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550132/
https://www.ncbi.nlm.nih.gov/pubmed/30989775
http://dx.doi.org/10.1111/cas.14025

Ejemplares similares